

Financial Disclosure

I work for Horizon Pharmaceuticals







Same dose as adults
2 shots, 3 weeks apart
Side effect profile similar to adult
except for increased incidence of
myocarditis



5 - 12 year olds

14 allu bluci

1/3 dose of the adult version
Same immune response
2 shots, 3 weeks apart
Decreased side effect profile; not
enough data about myocarditis

FORGO VACCINE: REASON #1

TOO FAST/NOT TESTED

Expedited process due to removal of barriers:

- Financial
- Ease of finding enrollees
- Same number of people in the studies
- Same scrutiny by FDA/CDC
- Same approval process





- Lost school time
- School/classroom closures
- · MIS-C
- Cardiac issues seen in moderate cases
- Unknown Long Term Issues
- Risk to others
- Over 60,000 hospitalizations





FORGO VACCINE: REASON #3 FERTILITY AND MENSTRUAL CONCERNS

- Question was raised because the COVID spike protein resembles a placental protein. Concern that antibodies would disrupt that protein leading to miscarriage.
- No increase in the rate of miscarriage following vaccination.

THIS BECAME THE SPARK FOR THE WILD FIRE OF FERTILITY ISSUES.

 Heavy bleeding following vaccine is being studied now. FORGO VACCINE: REASON #5

MYOCARDITIS

- Occurs with other viral illnesses,
 COVID, and following vaccine
- Frequency of vaccine related myocarditis increases with lower age.
- Dose of vaccine for 5-12 year olds is 1/3 of that of adults to help reduce this risk while still providing equal immune response.



TABLE 2. Individual-level estimated number of COVID-19 cases and COVID-19-associated hospitalizations, intensive care unit admissions, and deaths prevented after use of 2-dose mRNA COVID-19 vaccine for 120 days and number of myocarditis cases expected per million second mRNA vaccine doses administered, by sex and age group* — United States, 2021

	No. per million vaccine doses administered in each age group (yr:							
Sex/Benefits and harms from mRNA vaccination	12-29	12–17	18-24	25-29	≥30			
Male								
Benefit								
COVID-19 cases prevented [§]	11,000	5,700	12,100	15,200	15,300			
Hospitalizations prevented	560	215	530	936	4,598			
CU admissions prevented	138	71	127	215	1,242			
Peaths prevented	6	2	3	13	700			
Harms								
Myocarditis cases expected¶	39-47	56-69	45-56	15-18	3-4			

TABLE. Frequency of and risk for myocarditis among patients with and without COVID-19 and adjusted* myocarditis risk differences and risk ratios comparing patients with and without COVID-19 — Premier H Database Special COVID-19 Release, United States, March 2020-January 2021

Characteristic	No. of patients with COVID-19	No. of patients without COVID-19	No. of patients with myocarditis	Myocarditis among patients with COVID-		Myocarditis among patients without COVID-19		
				No. (% of patients with myocarditis)	Risk,	No. (% of patients with myocarditis)	Risk,	Adjusted myocarditis risk difference (95% CI)
Overall	1,452,773	34,552,521	5,069	2,116 (41.7)	0.146	2,953 (58.3)	0.009	0.126 (0.112- 0.140)
Sex								
Male	680,722	14,339,356	3,008	1,274 (42.4)	0.187	1,734 (57.6)	0.012	0.165 (0.146- 0.183)
Female	772,051	20,213,165	2,061	842 (40.9)	0.109	1,219 (59.1)	0.006	0.100 (0.087– 0.113)
Age group, yrs								
<16	64,898	3,670,762	218	86 (39.4)	0.133	132 (60.6)	0.004	0.122 (0.065- 0.179)
16-24	123,865	3,067,575	511	121 (23.7)	0.098	390 (76.3)	0.013	0.088 (0.061– 0.115)

- MYOCARDITIS RATE FOR CHILDREN <169 INFECTED WITH COVID NEARLY 37X HIGHER THAN WOULD BE EXPECTED
- RATE OF MYOCARDITIS
 ASSOCIATED WITH
 VACCINE IS DRAMATICALLY
 LOWER (56-69 VS 1325 PER
 MILLION)



DINOISY THE PARENTING EXPERT

DRMOLLYOSHEA.COM
DRMOLLY@DRMOLLYOSHEA.COM





